Publication: Clinical Pharmacology & Therapeutics: Volume 117, Issue 2
Summary
Pompe disease is a rare and complex condition with severe infantile-onset (IOPD) and late-onset (LOPD) forms. To better understand treatment efficacy for IOPD patients, Sanofi’s team developed a quantitative systems pharmacology (QSP) Virtual Twin® model, leveraging Certara’s Virtual Twin technology, to compare the effects of avalglucosidase alfa vs. the current standard of care.
Author(s): Chanchala Kaddi, Mengdi Tao, Silke Bergeler, Kelly George, Hugo Geerts, Piet H. van der Graaf, Julie L. Batista, Meredith Foster, Catherine Ortemann-Renon, Atef Zaher, Kristina An Haack, Susana Zaph
Year: December 4, 2024
Find out how QSP modeling can help tackle your development challenges.
The largest global QSP team of experts is ready to provide tailored solutions for your specific needs. Connect with us to optimize therapeutic strategies with cutting-edge QSP technology and expert-led guidance.
